Present and Future of Antibiotic Treatment for Carbapenem-Resistant Enterobacteriaceae

Dear Colleagues,

Carbapenem-resistant Enterobacteriaceae (CRE) infections have emerged as a major public health concern over the past few decades. The rise in CRE strains, characterized by their resistance to carbapenem antibiotics, has posed significant challenges in clinical management and treatment. As the arsenal of effective antibiotics continues to dwindle, it is imperative to explore new strategies and approaches to combat the threat of CRE infections.

This Special Issue aims to shed light on the present and future of antibiotic treatment for CRE, focusing on the latest research advancements, clinical trials, and therapeutic interventions. By bringing together research from various disciplines, including microbiology, pharmacology, and clinical medicine, this collection of articles aims to provide a comprehensive overview of the current landscape and prospects in the fight against CRE.

We invite researchers, clinicians, and industry professionals to contribute their insights and findings to this Special Issue. We will delve into the mechanisms underlying carbapenem resistance in Enterobacteriaceae, explore novel therapeutic targets and approaches, and discuss the challenges and opportunities in developing new antibiotics. Additionally, we will examine the role of alternative treatment options such as combination therapies, antimicrobial stewardship, and infection prevention and control measures. By fostering collaboration and knowledge exchange, we hope to catalyze advancements in antibiotic treatment for CRE and ultimately improve patient outcomes.

In addition, Dr. Dalida Bivona from the Biomedical and Biotechnological Sciences Department, University of Catania, will be a co-worker to help care for this Special Issue.

Dr. Dafne Bongiorno
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• carbapenem-resistant enterobacteriaceae
• antibiotic treatment
• antimicrobial resistance
• infection prevention
• novel therapeutic targets and approaches